Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

被引：35
|
作者：
Lorusso, D. [3 ]
Scambia, G. [3 ]
Amadio, G. [3 ]
di Legge, A. [3 ]
Pietragalla, A. [3 ]
De Vincenzo, R. [3 ]
Masciullo, V. [3 ]
Di Stefano, M. [3 ]
Mangili, G. [5 ]
Citterio, G. [4 ]
Mantori, M. [1 ]
Lambiase, A. [1 ]
Bordignon, C. [1 ,2 ]
机构：
[1] MolMed, Milan, Italy
[2] Univ Vita Salute San Raffaele, I-20132 Milan, Italy
[3] Univ Cattolica Sacro Cuore, Dept Gynecol Oncol, Rome, Italy
[4] Ist Sci San Raffaele, Dept Oncol, I-20132 Milan, Italy
[5] Ist Sci San Raffaele, Dept Gynecol Oncol, I-20132 Milan, Italy
来源：
BRITISH JOURNAL OF CANCER | 2012年 / 107卷 / 01期
关键词：
NGR-hTNF; vascular targeting agent; doxorubicin; ovarian cancer; TUMOR-NECROSIS-FACTOR; PEGYLATED LIPOSOMAL DOXORUBICIN; VASCULAR-TARGETING AGENT; ANTITUMOR-ACTIVITY; DRUG PENETRATION; TNF-ALPHA; T-CELLS; GEMCITABINE; TRIAL; ENHANCEMENT;
D O I：
10.1038/bjc.2012.233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BACKGROUND: The NGR-hTNF (asparagine-glycine-arginine-human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood vessels. METHODS: Patients progressing after >= 1 platinum/taxane-based regimen received NGR-hTNF 0.8 mu g m(-2) and doxorubicin 60 mg m(-2) every 3 weeks. Primary endpoint was a Response Evaluation Criteria in Solid Tumors-defined response rate with a target of more than 6 out of 37 responding patients. RESULTS: A total of 37 patients with platinum-free interval lower than 6 months (PFI < 6; n = 25), or between 6 and 12 months (PFI = 6-12; n = 12) were enrolled. Median baseline peripheral blood lymphocyte count (PBLC) was 1.6 per ml (interquartile range, 1.2-2.1). In all, 18 patients (49%) received more than 6 cycles. Febrile neutropaenia was registered in one patient (3%). Among 35 assessable patients, 8 (23%; 95% CI 12-39%) had partial response (2 with PFI < 6; 6 with PFI = 6-12) and 15 (43%) had stable disease (10 with PFI < 6; 5 with PFI = 6-12). Median progression-free survival (PFS) was 5.0 months for all patients, 3.8 months for patients with PFI < 6, and 7.8 months for patients with PFI = 6-12. Median overall survival (OS) was 17.0 months. Patients with baseline PBLC higher than the first quartile had improved PFS (P = 0.01) and OS (P = 0.001). CONCLUSION: Tolerability and activity of this combination warrant further randomised testing in patients with PFI < 6. The role of PBLC as a blood-based biomarker deserves further investigation. British Journal of Cancer (2012) 107, 37-42. doi:10.1038/bjc.2012.233 www.bjcancer.com Published online 29 May 2012 (C) 2012 Cancer Research UK
引用
收藏
页码：37 / 42
页数：6
相关论文
共 50 条
  • [31] NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
    De Vincenzo, F.
    Rossoni, G.
    Santoro, A.
    Gregorc, V.
    Zucali, P. A.
    Citterio, G.
    Simonelli, M.
    Petrella, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study
    Rimassa, L.
    Santoro, A.
    Sobrero, A. F.
    Sclafani, F.
    Gregorc, V.
    Andretta, V.
    Tronconi, M. C.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340
  • [33] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    Gregorc, V.
    Rimassa, L.
    De Braud, F. G.
    Rossoni, G.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 395 - 395
  • [34] A four-arm randomized phase II trial with NGR-hTNF given at low or high dose with or without doxorubicin in soft tissue sarcomas (STS).
    Ferrari, Stefano
    Casali, Paolo G.
    Blay, Jean-Yves
    Le Cesne, Axel
    Giuseppe, Tonini
    Ali, Nasim
    Perfetti, Vittorio
    Palmerini, Emanuela
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] PHASE I TRIAL WITH NGR-HTNF: PREDICTIVE POTENTIAL OF CYTOKINES AND ANGIOGENIC FACTORS (CAFS)
    Rossoni, G.
    Gregorc, V.
    Citterio, G.
    Spreafico, A.
    Donadoni, G.
    Vitali, G.
    Borri, A.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 182 - 182
  • [36] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
    Rimassa, L.
    Sobrero, A. F.
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Citterio, G.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) - Preliminary Results
    Gregorc, V.
    Zilembo, N.
    Grossi, F.
    Rossoni, G.
    Pietrantonio, F.
    Rijavec, E.
    Citterio, G.
    Platania, M.
    Lambiase, A.
    Bordignon, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S596 - S596
  • [39] Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens
    Sobrero, A. F.
    Pessino, A.
    Andretta, V.
    Bennicelli, E.
    Fornarini, G.
    Caprioni, F.
    Comandini, D.
    Orsino, L.
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 341 - 341
  • [40] PHASE IB STUDY TO DEFINE THE OPTIMAL LOW DOSE OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), IN COMBINATION WITH CISPLATIN IN PATIENTS (PTS) WITH SOLID TUMOURS
    Gregorc, V.
    De Braud, F. G.
    De Pas, T. M.
    Citterio, G.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 160 - 160
12345